Analysis of a cohort of 364 patients with stage I–IV CRC showed that SMAD4 deficiency was associated with higher tumour and nodal staging, the use of adjuvant therapy, fewer tumour infiltrating lymphocytes (TIL), lower peritumour lymphocyte aggregation (PLA) scores, and poorer RFS. The gene discussed is SMAD4; the disease is neoplasm.